Chemomab Receives RegulatoryApproval to Commence a Phase IIClinical Trial for CM-101

SBIJI Innovation
Aug 19, 2020
1 min read

July 21, 2020

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that it has received all necessary regulatory approvals in the UK and Israel, to commence a Phase IIa clinical trial for CM-101 as treatment for Primary Sclerosing Cholangitis (PSC).

Recent Posts

See All

Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™

October 16, 2024 Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales...

Secret Double Octopus Secures Strategic Investment from SBI Holdings to Propel Global Expansion of Workforce Passwordless Authentication

October 29, 2024 MENLO PARK, Calif.–( BUSINESS WIRE )–Secret Double Octopus, the market leader in workforce passwordless authentication,...

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...

Chemomab Receives RegulatoryApproval to Commence a Phase IIClinical Trial for CM-101

Recent Posts

Comments

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved